Overview

Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
Aventis Pharmaceuticals
Treatments:
Amifostine
Cisplatin
Docetaxel